TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
29.19
-0.08 (-0.27%)
Mar 9, 2026, 4:00 PM EDT - Market closed
TG Therapeutics Revenue
In the year 2025, TG Therapeutics had annual revenue of $616.29M with 87.32% growth. TG Therapeutics had revenue of $192.57M in the quarter ending December 31, 2025, with 78.00% growth.
Revenue (ttm)
$616.29M
Revenue Growth
+87.32%
P/S Ratio
6.99
Revenue / Employee
$1,544,579
Employees
399
Market Cap
4.31B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 616.29M | 287.28M | 87.32% |
| Dec 31, 2024 | 329.00M | 95.34M | 40.80% |
| Dec 31, 2023 | 233.66M | 230.88M | 8,290.02% |
| Dec 31, 2022 | 2.79M | -3.90M | -58.36% |
| Dec 31, 2021 | 6.69M | 6.54M | 4,300.66% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.07B |
| Amicus Therapeutics | 634.21M |
| ADMA Biologics | 510.17M |
| Ligand Pharmaceuticals | 268.09M |
| Centessa Pharmaceuticals | 15.00M |
| Crinetics Pharmaceuticals | 7.70M |
TGTX News
- 22 hours ago - Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis - GlobeNewsWire
- 3 days ago - TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting - GlobeNewsWire
- 7 days ago - Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis - Business Wire
- 10 days ago - TG Therapeutics: 'Strong Buy' On BRIUMVI's Massive Growth And Possible Expansion - Seeking Alpha
- 11 days ago - TG Therapeutics, Inc. (TGTX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance - GlobeNewsWire
- 14 days ago - TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update - GlobeNewsWire
- 4 weeks ago - TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis - GlobeNewsWire